Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Desmond Curran

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Clinical Drug Investigation|November 1, 2017
Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort StudyAkiko Mizukami, Keiko Sato, Koichi Adachi, et al.
BMJ Open|May 8, 2019
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programmeDesirée A M van Oorschot, Manjit Hunjan, Benjamin Bracke, et al.
Human Vaccines & Immunotherapeutics|December 9, 2024
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United StatesElizabeth M La, Jonathan Graham, David Singer, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTCPierre G M Scalliet, Vincent Remouchamps, Desmond Curran, et al.
Infectious Diseases and Therapy|March 20, 2024
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United StatesDaniel Molnar, Elizabeth M La, Frederik Verelst, et al.
Applied Health Economics and Health Policy|June 29, 2019
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian AdultsAshleigh McGirr, Desiree Van Oorschot, Robyn Widenmaier, et al.
Public Health in Practice (Oxford, England)|March 27, 2023
Lifetime risk of herpes zoster in the population of Beijing, ChinaChrista Lee, Nikolaos Giannelos, Desmond Curran, et al.
Human Vaccines & Immunotherapeutics|July 15, 2017
Assessment of the potential public health impact of Herpes Zoster vaccination in GermanyDesmond Curran, Desirée Van Oorschot, Lijoy Varghese, et al.
Influenza and Other Respiratory Viruses|January 4, 2022
Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross-sectional studyDesmond Curran, Eliazar Sabater Cabrera, Benjamin Bracke, et al.
Human Vaccines & Immunotherapeutics|August 22, 2018
Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years oldDesirée Van Oorschot, Anastassia Anastassopoulou, Barbara Poulsen Nautrup, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Clinical Drug Investigation|November 1, 2017
Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort StudyAkiko Mizukami, Keiko Sato, Koichi Adachi, et al.
BMJ Open|May 8, 2019
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programmeDesirée A M van Oorschot, Manjit Hunjan, Benjamin Bracke, et al.
Human Vaccines & Immunotherapeutics|December 9, 2024
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United StatesElizabeth M La, Jonathan Graham, David Singer, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTCPierre G M Scalliet, Vincent Remouchamps, Desmond Curran, et al.
Infectious Diseases and Therapy|March 20, 2024
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United StatesDaniel Molnar, Elizabeth M La, Frederik Verelst, et al.
Applied Health Economics and Health Policy|June 29, 2019
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian AdultsAshleigh McGirr, Desiree Van Oorschot, Robyn Widenmaier, et al.
Public Health in Practice (Oxford, England)|March 27, 2023
Lifetime risk of herpes zoster in the population of Beijing, ChinaChrista Lee, Nikolaos Giannelos, Desmond Curran, et al.
Human Vaccines & Immunotherapeutics|July 15, 2017
Assessment of the potential public health impact of Herpes Zoster vaccination in GermanyDesmond Curran, Desirée Van Oorschot, Lijoy Varghese, et al.
Influenza and Other Respiratory Viruses|January 4, 2022
Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross-sectional studyDesmond Curran, Eliazar Sabater Cabrera, Benjamin Bracke, et al.
Human Vaccines & Immunotherapeutics|August 22, 2018
Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years oldDesirée Van Oorschot, Anastassia Anastassopoulou, Barbara Poulsen Nautrup, et al.
Pageof 9